Your browser doesn't support javascript.
loading
Effect of probiotics at different intervention time on glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Wang, Xinghui; Chen, Lu; Zhang, Chunling; Shi, Qing; Zhu, Lei; Zhao, Sisi; Luo, Zhiqin; Long, Yirun.
Affiliation
  • Wang X; School of Nursing, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
  • Chen L; Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
  • Zhang C; Department of Nutrition, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
  • Shi Q; Department of Nutrition, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
  • Zhu L; School of Nursing, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
  • Zhao S; School of Nursing, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
  • Luo Z; School of Nursing, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
  • Long Y; School of Nursing, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Front Endocrinol (Lausanne) ; 15: 1392306, 2024.
Article in En | MEDLINE | ID: mdl-39114293
ABSTRACT

Background:

Type 2 diabetes mellitus(T2DM) is characterized by hyperglycemia. Gut microbiome adjustment plays a positive part in glucose regulation, which has become a hotspot. Probiotics have been studied for their potential to control the gut flora and to treat T2DM. However, the conclusion of its glucose-lowering effect is inconsistent based on different probiotic intervention times.

Objectives:

To comprehensively evaluate how various probiotic intervention times affect glycemic control in people with T2DM.

Methods:

We retrieved PubMed, Embase, Web of Science, and Cochrane Library on randomized controlled trials(RCTs)regarding the impact of probiotics on glycemic control in patients with T2DM from the inception to November 16, 2023. Separately, two researchers conducted a literature analysis, data extraction, and bias risk assessment of the involved studies. We followed the PRISMA guidelines, used RevMan 5.4 software for meta-analysis, and assessed the risk of bias by applying the Cochrane Handbook for Systematic Reviews 5.1.0.

Results:

We included eight RCTs with 507 patients. Meta-analysis revealed that the use of probiotics might considerably reduce levels of glycosylated hemoglobin (HbA1c) {mean deviation (MD) = -0.33, 95% confidence interval (CI) (-0.59, -0.07), p = 0.01}, Insulin {standard mean deviation (SMD) = -0.48, 95% CI (-0.74, -0.22), p = 0.0003} and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR){SMD = -1.36, 95% CI (-2.30, -0.41), p = 0.005} than placebo group. No statistically significant differences were found regarding fasting blood glucose (FBG) and body mass index (BMI) {SMD = -0.39, 95% CI (-0.83, 0.05), p = 0.08}, {SMD = -0.40, 95% CI (-1.07, 0.27), p = 0.25}, respectively. Subgroup analyses, grouped by intervention times, showed that six to eight weeks of intervention improved HbA1c compared to the control group (p < 0.05), both six to eight weeks and 12-24 weeks had a better intervention effect on Insulin, and HOMA-IR (p < 0.05).In contrast, there was no statistically significant variation in the length between FBG and BMI regarding duration.

Conclusion:

This meta-analysis found probiotics at different intervention times play a positive role in modulating glucose in T2DM, specifically for HbA1c in six to eight weeks, Insulin and HOMA-IR in six to eight weeks, and 12-24 weeks. To confirm our findings, further excellent large-sample research is still required. Systematic review registration https//www.crd.york.ac.uk/prospero, identifier CRD42023483325.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Glucose / Probiotics / Diabetes Mellitus, Type 2 / Glycemic Control Limits: Humans Language: En Journal: Front Endocrinol (Lausanne) Year: 2024 Document type: Article Affiliation country: China Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Glucose / Probiotics / Diabetes Mellitus, Type 2 / Glycemic Control Limits: Humans Language: En Journal: Front Endocrinol (Lausanne) Year: 2024 Document type: Article Affiliation country: China Country of publication: Switzerland